CAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- 1 July 2020
- journal article
- letter
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 20 (7) , 490-491
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- A Model-Independent Method to Determine Restricted Mean Survival Time in the Analysis of Survival CurvesSN Comprehensive Clinical Medicine, 2019
- Recent Advances in CAR-T Cell Therapy for Non-Hodgkin LymphomaClinical Lymphoma Myeloma and Leukemia, 2019
- Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular StudiesCirculation, 2019
- Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term SurvivorsFrontiers in Oncology, 2019
- The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 TrialJAIDS Journal of Acquired Immune Deficiency Syndromes, 2019
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2019
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyBlood, 2017
- Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled TrialsJournal of Clinical Oncology, 2016
- The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubtStatistics in Medicine, 2011